Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
My mother is a strong, intelligent, beautiful woman & also a cancer survivor.
— Las Vegas Ape🦍 (@lasvegas_ape) December 5, 2022
So my blood is still boiling over MMs like Citadel spoofing a potential "breakthrough" in cancer treatment 😡😡😡 Apes will break you Kenny🦍🦍🦍 #CitadelScandal #NWBO #AMC #GMEhttps://t.co/G4xZC5NnOC
My prognosis in 2015, 12 to 18 months to live. Luckily I had no idea who @adamfuerstein was and for that matter @statnews either. I was busy trying to stay alive. 8 years later and I’m still here. #DCVax UCLA Thank you Dr.Linda Liau for giving me 8 yrs with my son. NWBO
— Thomas Owen McCaffrey (@ThomasOwenMcCa1) December 5, 2022
Thank you Stonk.
won't open for me. can you give any details please
A cancer-focused biotechnology company has sued eight of the US’s largest market-making traders including Citadel Securities $NWBOhttps://t.co/TaeUeRzMhN
— Moon Market (@MoonMarket_) December 5, 2022
JS 40. Centerline for the Nice Real Big Move. like 8-10$ ?
The investigators concluded, “In this study, adding DCVax-L to standard of care resulted in clinically meaningful and statistically significant extension of survival for patients with both newly diagnosed glioblastoma and recurrent glioblastoma compared with contemporaneous, matched external controls who received standard of care alone.”
MHRA decision imminent, approval = $10.00+
FDA approval = $50.00+ using standard biotech multiple of 15 times forward looking PE.
Big pharmaceutical is not sleeping on the wheel, talks behind the scenes could materialize any moment now.
$NWBO ASCO just out: In an externally controlled phase III trial reported in JAMA Oncology, Liau et al found that the addition of an autologous tumor lysate–loaded dendritic cell vaccine (DCVax-L) to standard of care improved survival in patients with newly diagnosed glioblastoma and recurrent glioblastoma compared with contemporaneous external control patients receiving standard of care.
$NWBO Gap filled touch boom on very heavy volume. We could get MHRA approval news today then Kaboom $10.00+
Hedgle fund Harlot/Shermuta AF won’t be able to stop the most violent uptick in history of Wall Street that is imminently coming here any moment now. NWBO has no options, you have to buy the common on otcbb to be a part of this Paradigm shift in cancer treatment.
MHRA imminent positive decision will bury shorts alive.
Management has put the hedge fund manipulators on notice with massive lawsuit.
SEC and DOJ is watching this now.
Who dare go short over the weekend!!
my thoughts also I will leave it to the experts on our board.
Beartrap. yes interesting
Enigma: Bullet #4 is the most interesting. What is it and how so? $NWBO
— Michael Bigger (@biggercapital) December 1, 2022
lol true
Senti. I think they must be very concerned if they're already trying to defend it. If they really felt that it wasn't a case then they wouldn't waste a second, or a penny trying to plead their case. Its on and they know it.
senti. great point
and a lot of little helpers.
surprise, surprise !!!!
Sojo. The volume picked up a little second half of the day
Ty. lol
Hi Sojo/Judge. any forecast with the charts
Search News
Back to News Overview
Biotech Company Says Citadel Securities, Other Big Traders Manipulated Its Stock Price -- Update
Today 1:09 PM ET (Dow Jones)Print
By Justin Baer
A biotechnology company accused Citadel Securities LLC, Susquehanna International Group LLP and other Wall Street firms of driving down its stock price through a series of illicit trading tactics.
In a lawsuit filed Thursday in Manhattan federal court, Northwest Biotherapeutics Inc. alleged the market makers had repeatedly engaged in "spoofing," where traders place orders with an intent to fool other investors about a stock's demand and manipulate the price.
Northwest, whose shares trade over the counter, also sued Canaccord Genuity Inc., G1 Execution Services LLC, GTS Securities LLC, Instinet LLC, Lime Trading Corp. and Virtu Americas LLC.
"This frivolous lawsuit appears to be nothing more than an attempt by Northwest Biotherapeutics to divert attention away from its long history of governance and management failures, SEC charges for financial reporting lapses, and lawsuits from its own shareholders," a Citadel Securities spokesman said. "We intend to pursue any and all legal action against Northwest Biotherapeutics for making these false and baseless allegations, which only undermine the integrity of our capital markets."
Northwest's shares trade at about 83 cents. In 2019, the company settled allegations by the U.S. Securities and Exchange Commission that it failed to maintain internal control over its financial reporting.
A spokesman for Nomura, which owns Instinet, declined to comment. A spokesman for Virtu had no immediate comment. The other firms didn't immediately respond to requests for comment.
MUST HAVR HIT A NERVE.
"We have the hard data," said Laura Posner, a partner with Cohen Milstein Sellers & Toll who is representing Northwest. "It's hard to dispute actual transactions and patterns."
Spoofing, which was outlawed in 2010, has been at the center of a yearslong campaign by U.S. authorities to root out market manipulation. In August, a federal jury in Chicago convicted two former JPMorgan Chase & Co. traders who had been charged with spoofing in the gold market.
In the modern stock market, high-speed trading firms such as Citadel Securities and Susquehanna provide stock quotes throughout the day, executing orders from other investors while collecting a thin spread between the buying and selling price of the shares.
It is unclear from the data cited in the suit whether the alleged spoofing orders were placed on behalf of other investors, or by the firms themselves.
But Northwest argued that these market makers knew it was unlawful to execute the alleged trading tactics and should have had procedures in place to detect and prevent them.
The market makers, Northwest wrote, "deliberately engaged in repeated spoofing that interfered with the natural forces of supply and demand and drove (the company's) share price downward over the course of the relevant period."
Northwest said the alleged spoofing orders, which occurred between December 2017 and August 2022, battered the stock price even as the company released positive results from the trial of its lead product, a brain cancer treatment. In its suit, the company wrote that it had sold more than 49 million shares to raise money "at artificially depressed prices."
"One of the telltale signs of a manipulative spoofer is a rapid reversal of trading direction -- a lot of sell orders, followed by buy orders, followed by the cancellation of sell orders -- which suggest the original sell orders were not intended to be executed, but were merely a ploy to drive the price down to 'buy low,'" Northwest said in its complaint.
The company said it found thousands of spoofing episodes involving tens of millions of "baiting orders" over a five-year span, and was able to identify the market participants using trading data.
Write to Justin Baer at justin.baer@wsj.com
Corrections & Amplifications
Northwest Biotherapeutics Inc. is suing Citadel Securities LLC and other Wall Street firms. An earlier version of this article incorrectly said the biotechnology company was suing Citadel LLC. (Corrected on Dec. 1)
Thinking Combo Partnerships $NWBO
— Michael Bigger (@biggercapital) December 1, 2022
A new glioblastoma treatment improved outcomes for many patients in a phase 3 clinical study.
— UNC Health (@UNC_Health_Care) November 29, 2022
Matt Ewend, MD, in the UNC Department of Neurosurgery and at UNC Lineberger, led the trial site at the N.C. Basnight Cancer Hospital. #cancer #glioblastoma https://t.co/onUo7hQDIM
Hi Grip. a dip or good place to buy is there difference ? how's it looking on your chart?
scotty thanks for the Tell. I will buy the dip
in any language its great news.
https://www.ariva.de/news/northwest-biotherapeutics-reports-positive-top-line-results-10430508
1Department of Neurosurgery, University of California, Los Angeles
2King’s College Hospital, London, United Kingdom
3Department of Neurosurgery, Penn Brain Tumor Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia
4Division of Neurology, Washington University School of Medicine in St Louis, St Louis, Missouri
5Givens Brain Tumor Center, Abbott Northwestern Hospital, Minneapolis, Minnesota
6Columbia University Irving Medical Center, New York, New York
7New York-Presbyterian Hospital, New York, New York
8Preston A. Wells, Jr. Center for Brain Tumor Therapy, Division of Neuro-Oncology, Lillian S. Wells Department of Neurosurgery, University of Florida College of Medicine, Gainesville
9Department of Neurological Surgery, Washington University School of Medicine in St Louis, St Louis, Missouri
10Ben and Catherine Ivy Center for Advanced Brain Tumor Treatment, Swedish Medical Center, Seattle, Washington
11Taubman Medical Center, University of Michigan, Ann Arbor
12Neuro-Oncology Program, Rutgers Cancer Institute of New Jersey, New Brunswick
13Sutter Health, Sacramento, California
14Glasser Brain Tumor Center, Atlantic Healthcare, Summit, New Jersey
15Department of Neurological Sciences, Rush Medical College, Chicago, Illinois
16Department of Neurology, The Ohio State University, Columbus
17The Cancer Center of Columbus Regional Health, Columbus, Indiana
18University of Rochester, Rochester, New York
19University of Cincinnati, Cincinnati, Ohio
20John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey
21Department of Neurosurgery, Henry Ford Health System, Detroit, Michigan
22Department of Neurology and Chao Family Comprehensive Cancer Center, University of California, Irvine
23Rhode Island Hospital, Providence
24Long Island Brain Tumor Center at NSPC, Lake Success, New York
25Department of Neurosurgery, University of Colorado Health Sciences Center, Boulder
26Ascension St Thomas Brain and Spine Tumor Center, Howell Allen Clinic, Nashville, Tennessee
27Mays Cancer Center at UT Health San Antonio, San Antonio, Texas
28Department of Neurosurgery, UNC School of Medicine and UNC Health, Chapel Hill, North Carolina
29The Geisel School of Medicine at Dartmouth, Hanover, New Hampshire
30Advent Health, Kansas City, Kansas
31Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, California
32Division of Neuro-Oncology, Icahn School of Medicine at Mount Sinai, New York, New York
33Saint Joseph’s Hospital, Orange, California
34Jefferson Hospital for Neurosciences, Jefferson University, Philadelphia, Pennsylvania
35Department of Neurological Surgery, Vanderbilt University Medical Center, Nashville, Tennessee
36Beth Israel Deaconess Medical Center, Harvard Medical School, Cambridge, Massachusetts
37Baylor Scott & White Neuro-Oncology Associates, Dallas, Texas
38Illinois Cancer Care, Galesburg, Peoria
39Medical University of South Carolina Neurosciences, Charleston
40Mount Sinai Medical Center, Miami Beach, Florida
41Uniklinikum Dresden, Dresden, Germany
42Hollings Cancer Center, Medical University of South Carolina, Charleston
43Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida
44BG Klinikum Bergmannstrost, Halle, Germany
45Neurochirurgie Katharinenhospital, Klinikum der Landeshauptstadt Stuttgart, Stuttgart, Germany
46Seidman Cancer Center, University Hospitals–Cleveland Medical Center, Cleveland, Ohio
47Department of Neurosurgery, Tufts Medical Center, Boston, Massachusetts
48Piedmont Physicians Neuro-Oncology, Piedmont Brain Tumor Center, Atlanta, Georgia
49Department of Neuro-Oncology, Moffitt Cancer Center
50Pacific Neurosciences Institute and Saint John’s Cancer Institute, Santa Monica, California
51Centre de Recherche du CHUS, Université de Sherbrooke, Sherbrooke, Quebec, Canada
52UC San Diego Moore’s Cancer Center, La Jolla, California
53Department of Neurosurgery, Houston Methodist Hospital, Houston, Texas
54Geisinger Neuroscience Institute, Danville, Pennsylvania
55Klinik für Neurochirurgie, Chemnitz, Germany
56Baptist Health System, San Antonio, Texas
57Saint Luke’s Cancer Institute, Kansas City, Missouri
58Departments of Neurosurgery and Medicine, The Warren Alpert Medical School of Brown University, Providence, Rhode Island
59Kaiser Permanente, Redwood City, California
60University of Kentucky Markey Cancer Center, Department of Medicine, Neurosurgery, and Neurology, University of Kentucky, Lexington
61Oklahoma University Health Science Center, Oklahoma City
62University College London Hospitals, London, United Kingdom
63Blue Sky Neurology/Neuro-Oncology, Englewood, California
64Department of Neurology and Neurosurgery, Montreal Neurological Institute-Hospital, McGill University, Montreal, Quebec, Canada
65Department of Neurosurgery, Zucker School of Medicine at Hofstra/Northwell, Uniondale, New York
66University of California, Los Angeles
ANY OTHER QUESTIONS ?
And the data was outstanding. Another thing I have hardly ever seen is a JAMA article with 67 named authors. Ms. Linda Powers has given this publication all she had, knowing full well that if there’s something that should shut the critics up for good, it would be from a publication like this with named authors who read like the who's who in glioblastoma expertise. [see appendix below for list of authors/affiliations.]